Ariadne and Aureus Pharma to Collaborate for Support of Knowledge Management Solutions
News May 26, 2010
Ariadne and Aureus are joining forces with the goal to deliver knowledge management solutions for the life sciences industry, and announce that Ariadne will distribute Aureus’ offerings in the US.
The two companies will initiate a collaboration to explore together further synergies between their respective knowledge management solutions and more particularly the interfaces between the protein pathway space and medicinal chemistry. Such interfaces will help customers to better understand mechanisms of actions between therapeutic proteins, protein pathways and small molecules and provide new insights in the disease biology area.
“This engagement highlights the ongoing evolution of Ariadne,” says Ilya Mazo, Ph.D. and CEO, “by partnering with best-in-class providers of knowledge management solutions. We can provide solutions that enable customers to take advantage of both Ariadne and Aureus’ products where it makes sense in their organization, workflow and informatics infrastructure. We believe that this collaboration will make it possible to offer the highest level of interoperability between our companies, along with improved solutions for knowledge management.”
“The partnership between Aureus and Ariadne will enable to support synergies in discovery and development workflows as used across multiple departments and scientific disciplines in the Life Science Industry,” says Jason Theodosiou, CEO of Aureus Pharma. “Both companies are innovative and have created solutions that organize high quality data from various sources to better identify, create, distribute, and enable knowledge integration within an organization.”
The collaboration will establish confidence between researchers in disease biology and medicinal chemistry that the technologies they use and deploy in their specific environments provide continuity in the pipeline discovery process, align common goals in knowledge management and increase scientific comprehension between these two groups.
Financial terms were not disclosed.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Computer Program Helps Find Ways to Repurpose Existing DrugsNews
Researchers have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, matches existing data about FDA-approved drugs to diseases, and predicts potential drug efficacy.READ MORE
Machine Learning: Helping Determine How a Drug Affects the BrainNews
Machine learning could improve our ability to determine whether a new drug works in the brain, potentially enabling researchers to detect drug effects that would be missed entirely by conventional statistical tests, finds a new UCL study published today in Brain.READ MORE